Global Opioid (Opium) Addiction Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

August 2019 | 95 pages | ID: GB15C1B105AEN
VPAResearch

Abstracts

High levels of pipeline activity are being observed in Opioid (Opium) Addiction treatment during 2019. Clinical development activities are being undertaken by more than 20 companies including Adapt Pharma Ltd, Addex Therapeutics Ltd, Amygdala Neurosciences Inc, Axim Biotechnologies Inc , BioCorRx Inc and others.

A Significant contribution to the Opioid (Opium) Addiction pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Opioid (Opium) Addiction pipeline included 24 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Opioid (Opium) Addiction condition and increased access to investments is encouraging growth of Opioid (Opium) Addiction drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Opioid (Opium) Addiction drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Opioid (Opium) Addiction therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Opioid (Opium) Addiction pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Opioid (Opium) Addiction. Further, orphan drug status, fast track designation, grants awarded and other special status for Opioid (Opium) Addiction pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Opioid (Opium) Addiction pipeline and formulate effective research and development strategies.

RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Opioid (Opium) Addiction Pipeline candidates-

• Pre-clinical Phase: Discovery, research, pre-clinical
• Early Phase: Phase 1 and Phase 2 Opioid (Opium) Addiction drugs
• Late phase: Phase 3 and in-approval Opioid (Opium) Addiction drugs

Companies involved in the Pipeline-

• Company overview
• Snapshot
• Opioid (Opium) Addiction therapeutic treatment activities

Details for each Opioid (Opium) Addiction drug candidate-

• Snapshot
• Drug Name
• Alternative Names
• Company
• Originator
• Phase
• Molecule Type
• Orphan Drug Status
• Drug Overview
• Mechanism of Action
• Current Status
• Trial Details

Other details

• Pre-clinical trials for each drug candidate
• Clinical trials for each drug candidate

Recent Opioid (Opium) Addiction therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 EXECUTIVE SUMMARY

2.1 Opioid (Opium) Addiction- Disease Overview
2.2 Opioid (Opium) Addiction- Pipeline Snapshot
2.3 Opioid (Opium) Addiction- Pipeline Drugs by Phase
2.4 Opioid (Opium) Addiction- Pipeline Drugs by Company
2.5 Opioid (Opium) Addiction- Pipeline Drugs by Mechanism of Action

3 COMPANY WISE PIPELINE ANALYSIS

3.1 Adapt Pharma Ltd Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.2 Addex Therapeutics Ltd Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.3 Amygdala Neurosciences Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.4 Axim Biotechnologies Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.5 BioCorRx Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.6 BioDelivery Sciences International Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.7 Camurus AB Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.8 Foresee Pharmaceuticals Co Ltd Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.9 Indivior Plc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.10 Insys Therapeutics Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.11 Kandy Therapeutics Ltd Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.12 Novartis AG Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.13 Omeros Corp Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.14 Opiant Pharmaceuticals Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.15 Orexigen Therapeutics Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.16 Orexo Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.17 Pfizer Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.18 Pharmazz Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.19 Relmada Therapeutics Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.20 Savant HWP Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.21 Serina Therapeutics Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.22 Titan Pharmaceuticals Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.23 Xalud Therapeutics Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019
3.24 Zynerba Pharmaceuticals Inc Opioid (Opium) Addiction Drug Pipeline, H2- 2019

4 PHASE 1 PIPELINE DRUG DETAILS

4.1 Opioid (Opium) Addiction- Phase 1 Drug Details
4.2 Opioid (Opium) Addiction- Phase 1 Drug Overview
4.3 Opioid (Opium) Addiction- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 PHASE 2 PIPELINE DRUG DETAILS

5.1 Opioid (Opium) Addiction- Phase 2 Drug Details
5.2 Opioid (Opium) Addiction- Phase 2 Drug Overview
5.3 Opioid (Opium) Addiction- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 PHASE 3 PIPELINE DRUG DETAILS

6.1 Opioid (Opium) Addiction- Phase 3 Drug Details
6.2 Opioid (Opium) Addiction- Phase 3 Drug Overview
6.3 Opioid (Opium) Addiction- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS

7.1 Opioid (Opium) Addiction- Pre-clinical Phase Drug Details
7.2 Opioid (Opium) Addiction- Pre-clinical Phase Drug Overview
7.3 Opioid (Opium) Addiction- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 RECENT NEWS AND DEVELOPMENTS

9 APPENDIX

9.1 About VPAResearch
9.2 Sources and Research Methodology